Wyeth has devoted more than 350 scientists to 23 separate research projects aimed at treating Alzheimer's. So far, that commitment has cost the giant drug developer more than $450 million. But while it's one of the most ambitious research projects in the world related to Alzheimer's, The New York Times concludes that a broad array of pharma and biotech companies are also looking for new therapies to treat a disease that is expected to claim millions of more victims as the populations of developed countries age. There's a payback at the end of that research. An effective treatment could command $20,000 a year per patient, making any possible approval a sure-fire blockbuster for years to come.
- read the report from The New York Times
ALSO: Alzheimer's disease researchers may be able to reduce the time and expense associated with clinical trials, according to early results from the Alzheimer's Disease Neuroimaging Initiative, a public-private research partnership organized by the National Institutes of Health. Release